Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
03/2010
03/17/2010EP1578928B1 Metalloprotease activation of myostatin, and methods of modulating myostatin activity
03/17/2010EP1513814B1 Novel piperidine compound
03/17/2010EP1506225B2 Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus
03/17/2010EP1385870B1 Peptides as ns3-serine protease inhibitors of hepatitis c virus
03/17/2010EP1303536B1 Novel fibroblast growth factor (fgf23) and methods for use
03/17/2010EP1027439B1 Multivalent antigen-binding proteins
03/17/2010CN201423029Y Novel multienzyme capsule
03/17/2010CN101675071A modified interferon beta polypeptides and their uses
03/17/2010CN101674844A tetrazolyl macrocyclic hepatitis c serine protease inhibitors
03/17/2010CN101674843A Composition for transmucosal delivery of polypeptides
03/17/2010CN101674842A Compositions and methods for treating alzheimer's disease and dementia
03/17/2010CN101674839A Process for producing osteocalcin-containing extract
03/17/2010CN101674812A Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
03/17/2010CN101674809A Self-precipitating pharmaceutical formulations for the modified release of active principle
03/17/2010CN101674805A High concentration factor vii polypeptide formulations comprising an aromatic preservative and an antioxidant
03/17/2010CN101671723A Haplotype consisting of single nucleotide polymorphism of kynureninase gene
03/17/2010CN101671397A Anti-EGFR single-chain antibody fusion Gelonin recombination immunotoxin, preparation method and usage thereof
03/17/2010CN101671396A Vascular endothelial growth factor specifically combined with collagen and application thereof
03/17/2010CN101671390A Human interferon alpha derivatives and preparation and use of pegylated products thereof
03/17/2010CN101671389A Erythrocyte generating characteristic-free erythropoietin with nervous protecting function and application thereof
03/17/2010CN101671388A Blood brain barrier penetrable erythropoietin (EPO) and application thereof
03/17/2010CN101671335A Cytotoxins, prodrugs, linkers and stabilizers useful therefor
03/17/2010CN101670119A polynucleotide
03/17/2010CN101670115A Compound of heparanase and heat shock protein, preparation method and applications thereof
03/17/2010CN101670114A Compound of survivin and heat shock protein, preparation method and applications thereof
03/17/2010CN101670099A Application of kynurenine aminotransferase in preparing medicament for treating hypertension
03/17/2010CN101670098A Application of restructured thymosin alpha source in preparation of medicine for preventing and treating fatty liver
03/17/2010CN101670097A Application of cartilage oligomeric matrix protein in preparing medicine for treating vascular-calcification
03/17/2010CN101670096A Medicinal preparation containing exenatide
03/17/2010CN101670095A Pharmaceutical composition for treating embolism and preparation method thereof
03/17/2010CN101670094A Compound gentamycin sulfate soluble powder and preparation method thereof
03/17/2010CN101670093A Drug composite for promoting livestock and poultry to grow and preparation method thereof
03/17/2010CN101670092A Method for preparing liver cell growth promoter freeze-drying powder injection for injecting
03/17/2010CN101669995A Composite for treatment and health care of heart cerebrovascular diseases and preparation method thereof
03/17/2010CN101669905A Thymosin alpha1 injection-type subcutaneous implant
03/17/2010CN101669900A Polymeric delivery formulations of leuprolide with improved efficacy
03/17/2010CN100594037C Complement receptor 2 targeted complement modulators
03/17/2010CN100594036C Animal medicine capable of rehabilitating intestinal tract injury
03/16/2010US7678895 oligonucleotide with modified phosphorothioate linkage, sugar moiety, or nucleobase; disease or condition associated with expression of superoxide dismutase 1
03/16/2010US7678890 Compositions and methods of treating disease with FGFR fusion proteins
03/16/2010US7678889 monoclonal antibody for identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and noncancerous disease states in the ovary
03/16/2010US7678888 preparing a powdered form of a protein by mixing a solution of the protein with inulin and tagatose, and drying the mixture; stable at room temperature; Blood substitutes
03/16/2010US7678887 Identification and cloning of a novel human gene, RET16, involved in the intracellular signaling cascade
03/16/2010US7678886 increased recombinant protein expression levels, solubility, soluble expression and stability, lower immunogenicity, and improved pharmacokinetics and/or pharmacodynamics
03/16/2010US7678885 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
03/16/2010US7678884 Biologically active peptide and agent containing the same
03/16/2010US7678833 Method to increase the bioavailability of cysteine
03/16/2010US7678782 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
03/16/2010US7678775 ILK inhibitors for the treatment of renal disease
03/16/2010US7678774 Treating severe acute respiratory syndrome
03/16/2010US7678771 comprising L-lysine-d-amphetamine or salts; for treating attention deficit hyperactivity disorder
03/16/2010US7678770 Abuse-resistant amphetamine prodrugs
03/16/2010US7678769 Hepatocyte growth factor receptor splice variants and methods of using same
03/16/2010US7678768 Physiologically-active composition based on collagen
03/16/2010US7678767 Glue compositions for lung volume reduction
03/16/2010US7678766 Process for the preparation of cyclosporin derivatives
03/16/2010US7678765 Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
03/16/2010US7678764 Protein formulations for use at elevated temperatures
03/16/2010US7678763 preparations of insulin and glucagon; for use when glucagon response to acute hypoglycemia is impaired or lost in patients with advanced Type 1 and Type 2 diabetes
03/16/2010US7678762 Methods for reducing the risk of hypoglycemia
03/16/2010US7678760 Inhibitors of Memapsin 2 and use thereof
03/16/2010US7678759 Diagnosis and treatment of neuroectodermal tumors
03/16/2010US7678758 For enhancing T cell response to tumour cells
03/16/2010US7678558 Method for overexpression of zwitterionic polysaccharides
03/16/2010US7678549 Polyphenol inhibition of nucleoside diphosphate kinase-B activity and cancer metastasis
03/16/2010US7678379 Mycobacterium tuberculosis epitopes and methods of use thereof
03/16/2010US7678378 Compounds for intracellular delivery of therapeutic moieties to nerve cells
03/16/2010US7678372 Tyrosine kinase inhibitors; anticancer agents; genetic engineered protein
03/16/2010US7678369 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents
03/16/2010US7678364 Dry powder; complex
03/16/2010CA2639525A1 Topical composition for the protection and/or treatment of radiation related skin damages
03/16/2010CA2510058C Improved pharmaceutical botulinum toxin compositions
03/16/2010CA2459981C For producing biologically active products
03/16/2010CA2436724C Use of inhibitors of dipeptidyl peptidase iv (dp iv) in combination with inhibitors of alanyl-aminopeptidase (apn)
03/16/2010CA2432006C Pharmaceutical preparation with retarding active ingredient release, method for its production and its use
03/16/2010CA2423616C Chemokine mutants in the treatment of multiple sclerosis
03/16/2010CA2422216C Method for the production of vitamin k-dependent proteins
03/16/2010CA2413769C Microneedle for delivering a substance into the dermis
03/16/2010CA2376986C Method for purification of proteins
03/16/2010CA2368617C Hydrogel-forming system with hydrophobic and hydrophilic components
03/16/2010CA2362772C Pharmaceutical formulation for intraveous or intramuscular octreotide administration
03/16/2010CA2327311C Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
03/16/2010CA2302838C Modulation of the sphingosine kinase signalling pathway
03/16/2010CA2296766C Aggrecan degrading metallo proteases
03/16/2010CA2200054C Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
03/16/2010CA2191577C Method for treating and preventing atherosclerosis
03/16/2010CA2160693C Oral drug delivery compositions and methods
03/12/2010CA2639562A1 Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
03/11/2010WO2010028131A1 Process for the preparation of pramlintide
03/11/2010WO2010028122A1 Process for making bivalirudin
03/11/2010WO2010028089A2 Agents and methods for treatment of pain
03/11/2010WO2010028055A1 Insulin with a basal release profile
03/11/2010WO2010027951A1 Compositions and methods for inhibiting entry of a hepatic virus
03/11/2010WO2010027831A1 Method for reducing scarring during wound healing using antisense compounds directed to ctgf
03/11/2010WO2010027828A2 Pd-1 antagonists and methods of use thereof
03/11/2010WO2010027802A2 Methods for treating diabetic wounds
03/11/2010WO2010027564A2 Amido anti-viral compounds, compositions, and methods of use
03/11/2010WO2010027473A2 Immunogenic escherichia coli heat stable enterotoxin
03/11/2010WO2010027405A2 Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration
03/11/2010WO2010027404A2 Stable solid formulation of therapeutic polypeptides suitable for oral administration
1 ... 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 ... 3163